Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Income from Continuing Operations: 2018-2024

Historic Income from Continuing Operations for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to -$322.1 million.

  • Avidity Biosciences' Income from Continuing Operations fell 117.13% to -$174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.5 million, marking a year-over-year decrease of 95.95%. This contributed to the annual value of -$322.1 million for FY2024, which is 52.18% down from last year.
  • Avidity Biosciences' Income from Continuing Operations amounted to -$322.1 million in FY2024, which was down 52.18% from -$211.6 million recorded in FY2023.
  • In the past 5 years, Avidity Biosciences' Income from Continuing Operations ranged from a high of -$44.3 million in FY2020 and a low of -$322.1 million during FY2024.
  • Over the past 3 years, Avidity Biosciences' median Income from Continuing Operations value was -$211.6 million (recorded in 2023), while the average stood at -$235.9 million.
  • Data for Avidity Biosciences' Income from Continuing Operations shows a maximum YoY crashed of 166.37% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Avidity Biosciences' Income from Continuing Operations stood at -$44.3 million in 2020, then slumped by 166.37% to -$117.9 million in 2021, then crashed by 47.47% to -$173.9 million in 2022, then fell by 21.67% to -$211.6 million in 2023, then tumbled by 52.18% to -$322.1 million in 2024.